Termination Of Karo Agreement With Pfizer

Termination of this agreement does not affect ongoing operations or business prospects. news.cision.com/karo-pharma/r/termination-of-karo-agreement-with-pfizer,c3027311 Carl Lindgren, VP Business Development, +4676-002 60 22, carl.lindgren@karopharma.com Christoffer Lorenzen, CEO, +4673-501 76 20, christoffer.lorenzen@karopharma.com HUDDINGE, Sweden, Feb. 4, 2020 /PRNewswire/ — Karo Pharma AB (“Karo”) has been informed by Pfizer Inc. (“Pfizer”) of its decision to terminate the research cooperation and licensing agreement between the two companies of the Decimabbe r 2011. After the deletion of this agreement, there will be no active cooperation agreements between the two companies. This information is information that Karo Pharma is required to publish under the EU Market Abuse Regulation. The information was provided by the aforementioned contact persons on February 4, 2020 submitted for publication at 6 p.m. Paris time. This information follows Pfizer`s decision to terminate a specific development project, PF-06763809, of which Karo was informed in press releases on November 5 and November 20, 2019. . You must be a logged-in subscriber to view this content. .

The orphan name is given by a regulator to encourage companies to develop drugs for rare diseases. Karo Pharma is a pharmaceutical company specializing in the sale and marketing of prescription drugs and non-prescription products sold in pharmacies and retail. Karo Pharma is listed on nasdaq Stockholm Mid Cap. If your organization has a subscription, you have several options that allow you to access AdisInsight even if you`re working remotely. If your organization doesn`t have a subscription to this content. Try one of the following steps to fully access the content and features of the AdisInsight database. This information has been made available to you by Cision news.cision.com. . . .